February 18, 2016 : Latest SGLT-2 Inhibitors News

LATEST NEWS

• Shifting Paradigm in Diabetes Treatment – An Interview with Dr. Vinik
• Empagliflozin/Linagliptin Combination with Metformin for Triple Therapy

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

• Supporters of New Classification of Diabetes

HOMERUN SLIDES — Great Clinical Presentation Highlights

• Diabetes for Cardiologists Part 9: SGLT-2 Inhibitors

According to IMS prescribing data, all of the SGLT-2 inhibitor class drugs are experiencing growth. What is more important is that the 6-month adherence rate is higher than any other branded class. Part of this can be attributed to the 2-year free medication vouchers that all manufacturers offer. However, if you look at the data on cardiovascular disease and weight loss in this month’s special edition, you get a good idea as to why prescribers are making this class of drugs their first choice after metformin.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief

How SGLT-2 inhibitors can provide new approach over treatment centered on attaining glycemic control, intensive therapy.

Two pills provided greater glucose-lowering efficacy than three with low hypoglycemia risk.

In part seven of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses the supporters of the new classification of diabetes, such as the role of SGLT-2 inhibitors in improving cardiovascular outcomes, reducing weight, and targeting treatments for the mediating pathways of hyperglycemia.

In this week’s Homerun Slides, surprising information about SGLT-2 inhibitors.